EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES

http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 13
Issue: 8
Year: 2026

A REVIEW ON BULK MANUFACTURING IN THE PHARMACEUTICAL INDUSTRY

Muskan Shabbir Shaikh*, Sarang D. Kulkarni, Dr. P. N. Sable, Mrs. Sharda S. Kulkarni

Department of Pharmaceutical Quality Assurance, S.S.P. Shikshan Sanstha's Siddhi College of Pharmacy, Chikhali, Pune, Maharashtra 411062, India.
Krishnarao Bhegade Institute of Pharamaceutical Education and Research Telegaon Dhabhade Behind Indrayani Mahavidyalaya Talegaon Chakan Road, Talegaon Dabhade, Maval, Maharashtra, Pune 410507.

***Corresponding Author: Muskan Shabbir Shaikh**

Department of Pharmaceutical Quality Assurance, S.S.P. Shikshan Sanstha's Siddhi College of Pharmacy, Chikhali, Pune, Maharashtra 411062, India.

DOI: https://doi.org/10.5281/zenodo.21702472

How to cite this Article: Muskan Shabbir Shaikh*, Sarang D. Kulkarni, Dr. P. N. Sable, Mrs. Sharda S. Kulkarni. (2026). A Review on Bulk Manufacturing In The Pharmaceutical Industry. European Journal of Biomedical and Pharmaceutical Sciences, 13(8), 74–82.

Article Received on 05/07/2026 **Article Revised on 25/07/2026** **Article Published on 01/08/2026**

ABSTRACT

Bulk pharmaceutical manufacturing, encompassing both active pharmaceutical ingredients (APIs) and large-scale drug product formulation, forms the foundation of the global healthcare supply chain. This review presents a structured overview of modern bulk manufacturing, including small-molecule chemical synthesis, biologics manufacturing, formulation unit operations, process scale-up, regulatory expectations, Quality by Design (QbD), Process Analytical Technology (PAT), Industry 4.0 solutions, sustainability, and supply-chain resilience. Traditional batch processing is compared with continuous manufacturing, with emphasis on technical advantages, implementation challenges, and quality-assurance implications. The review also highlights emerging manufacturing directions such as modular facilities, digital twins, mRNA platforms, and greener production systems. Overall, modern bulk manufacturing is moving from empirical, end-product testing models toward science-based, monitored, and digitally controlled systems that can improve process robustness, product quality, and patient access.

KEYWORDS: Bulk manufacturing; Active Pharmaceutical Ingredient; Biologics; Continuous manufacturing; Quality by Design; Process Analytical Technology; Green chemistry; Industry 4.0.[1]



Raw Materials	→	API / Biologic Production	→	Bulk Formulation	→	Quality Control	→	Packaging / Storage

Figure 1: Overview of the bulk pharmaceutical manufacturing workflow and lifecycle quality controls.

1. INTRODUCTION

Pharmaceutical manufacturing is undergoing a major transformation from fixed, batch-wise production toward flexible, science-based, and digitally enabled systems. For many decades, the industry relied primarily on discrete unit operations and final product testing. Although this approach has supported large-scale production, it can also create long cycle times, high inventory requirements, and delayed detection of process deviations.

Bulk manufacturing in the pharmaceutical context refers to the large-scale synthesis or biosynthesis of APIs and their conversion into bulk drug substances or bulk drug products before final packaging. Examples include crystallized APIs, purified monoclonal antibodies, granulates, blended powders, compressed tablets, large-volume parenterals, and stabilized intermediates for filling operations.

The current demand for affordable medicines, complex biologics, personalized therapies, and resilient supply chains requires manufacturing platforms that are scalable, controllable, and environmentally responsible. This review summarizes core manufacturing operations, scale-up considerations, quality frameworks, digital technologies, sustainability strategies, and future opportunities relevant to bulk pharmaceutical production.[2]

2. API Synthesis: Small Molecules and Biologics

Bulk manufacturing differs substantially according to the nature of the therapeutic product. Small-molecule APIs are commonly produced through multi-step organic synthesis, whereas biologics are generated using living systems such as bacteria, yeast, or mammalian cells. Each route has different equipment needs, process risks, and quality-control requirements.

Key comparison points

- Small molecules: chemically synthesized, impurity and polymorphism control are central.
- Biologics: produced by living systems, requiring close control of upstream and downstream conditions.
- Both pathways require robust validation, contamination control, and lifecycle documentation.[3]

2.1 Small-Molecule Chemical Manufacturing

Small-molecule manufacturing requires strict control of reaction kinetics, thermodynamics, impurity formation, solvent use, and crystallization conditions. Typical bulk operations include reaction, extraction, crystallization, filtration, washing, drying, milling, and blending.

Key technical focus areas include solvent recovery, impurity control, yield optimization, containment for potent compounds, and control of polymorphic form. Crystallization is particularly critical because changes in temperature profile, agitation, seed addition, or solvent composition can alter polymorphism, particle size distribution, solubility, bioavailability, and stability.

2.2 Large-Molecule Biomanufacturing

Biologics manufacturing uses living systems and therefore requires close monitoring of cell viability, pH, dissolved oxygen, temperature, nutrient feed, osmolality, and metabolite levels. Upstream processing includes cell culture or fermentation in large-scale bioreactors, while downstream processing focuses on purification, impurity clearance, concentration, and formulation.

Common downstream operations include centrifugation, depth filtration, chromatography, viral clearance, ultrafiltration, and diafiltration. The final bulk drug substance is frequently stabilized in a suitable buffer and stored under controlled conditions before fill-finish operations.[4]

3. Batch versus Continuous Manufacturing

Batch manufacturing processes a defined quantity of material through separated unit operations. Continuous manufacturing feeds raw materials into an integrated system while processed material is withdrawn at the same time. The shift toward continuous processing is one of the most important developments in modern pharmaceutical production because it supports smaller equipment footprints, real-time monitoring, and faster process decisions.

Continuous manufacturing is not simply a faster version of batch processing. It requires strong material tracking, validated control strategies, defined diversion logic, integrated PAT tools, and clear procedures for start-up, steady state, disturbance handling, and shutdown.[5]

Table 1: Comparison of batch and continuous manufacturing in bulk pharmaceutical production.

Parameter	Batch manufacturing	Continuous manufacturing	Quality impact
Footprint	Large equipment and holding areas	Compact, integrated units	Reduced transfer and storage risk
Scale-up	Larger equipment often required	Longer run time or parallel lines	Lower scale-up variability
Testing approach	Offline and end-product focused	In-line/online monitoring possible	Faster deviation detection
Material rejection	Whole batch may be impacted	Defined material diversion possible	Less material loss during disturbances
Investment profile	Lower initial investment but higher inventory	Higher automation cost but lower cycle time	Improved lifecycle efficiency

4. Formulation Unit Operations in Bulk Drug Product Manufacturing

Bulk drug product manufacturing converts APIs and excipients into processable intermediates or final dosage forms. The main operations for solid dosage forms include powder dispensing, blending, granulation, drying, milling, lubrication, compression, and coating. For sterile and biologic products, the workflow may include buffer preparation, sterile filtration, aseptic handling, filling, and controlled storage.

4.1 Powder Blending

Achieving uniform distribution of API in a bulk powder mixture is challenging because segregation can occur due to differences in particle size, density, shape, surface properties, and electrostatic behavior. V-blenders, bin blenders, double-cone blenders, and high-shear mixers are used depending on formulation and scale.

Blend scale-up often considers dimensionless parameters such as the Froude number to maintain comparable flow and shear conditions across equipment sizes. PAT tools such as NIR spectroscopy may be used to monitor blend uniformity and define the blending endpoint more scientifically than fixed-time mixing alone.[6]

4.2 Granulation and Drying

Granulation improves powder flowability, compressibility, and content uniformity. Wet granulation uses a binder liquid and may be performed using high-shear granulators or fluid-bed systems. Critical parameters include binder addition rate, impeller speed, chopper speed, inlet air temperature, air flow, humidity, and drying endpoint.

Dry granulation by roller compaction is preferred for moisture- or heat-sensitive APIs. The roll pressure, gap width, feed screw speed, and milling conditions influence ribbon density, granule strength, and downstream tablet performance.

4.3 Compression and Coating

High-speed tablet presses can produce very large quantities of tablets per hour and therefore require robust control of powder feed, compression force, dwell time, tooling condition, tablet weight, hardness, friability, and content uniformity. Coating processes require control of spray rate, atomization, pan speed, inlet/outlet temperature, and exhaust humidity.

Film coating may improve taste masking, appearance, stability, identification, and modified release behavior. For controlled-release products, small changes in coating thickness or uniformity may significantly affect dissolution performance.[7]

5. Process Engineering, Scale-Up, and Technology Transfer

Scale-up from laboratory or pilot scale to commercial bulk manufacturing is rarely linear. Larger equipment changes mixing patterns, heat transfer efficiency, mass transfer, residence time distribution, surface-area-to-volume ratio, and mechanical stress. These differences can affect impurity profiles, particle properties, biological cell health, and final product performance.

Engineering tools such as computational fluid dynamics, design of experiments, process modeling, and dimensionless numbers support scale-up decisions. Commonly used parameters include Reynolds number for flow regime, Power number for impeller energy consumption, Froude number for granular flow and blending, and Damköhler number for the relationship between reaction and transport rates.[8]

6. Regulatory Framework, Validation, and Quality by Design

Bulk pharmaceutical manufacturing is controlled by a strict regulatory framework designed to ensure product safety, efficacy, and quality. Major regulatory expectations include process validation, cleaning validation, equipment qualification, data integrity, documentation control, deviation management, and change control.

ICH guidelines provide a structured basis for pharmaceutical development and lifecycle management. ICH Q8 introduces pharmaceutical development and QbD concepts; ICH Q9 describes quality risk management; ICH Q10 defines the pharmaceutical quality system; ICH Q11 addresses development and manufacture of drug substances; and ICH Q13 supports continuous manufacturing implementation.[9]

Table 2: Selected ICH guidelines relevant to bulk pharmaceutical manufacturing.

Guideline	Main focus	Relevance to bulk manufacturing
ICH Q8	Pharmaceutical development	QTPP, CQAs, design space and process understanding
ICH Q9	Quality risk management	Risk identification, assessment, control and review
ICH Q10	Pharmaceutical quality system	Lifecycle approach, CAPA, change management and continual improvement
ICH Q11	Drug substance development and manufacture	API process development, control strategy and lifecycle considerations
ICH Q13	Continuous manufacturing	Scientific and regulatory considerations for continuous processes



Figure 2: Relationship between QbD, PAT, design space and continuous manufacturing control.

6.1 Quality by Design Approach

QbD builds quality into the product and process instead of relying only on final testing. It begins with the Quality Target Product Profile (QTPP), followed by identification of Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs). The design space describes combinations of variables that have been demonstrated to provide assurance of quality.

In a well-developed QbD system, manufacturing becomes more knowledge-driven. The process is monitored, controlled, and continually improved based on scientific understanding and risk-based prioritization.

7. Process Analytical Technology, Automation, and Industry 4.0

PAT provides timely measurements of material and process attributes during manufacturing. It supports process understanding, QbD, continuous verification, and potential real-time release testing. Common PAT tools include NIR spectroscopy, Raman spectroscopy, particle-size analyzers, pH probes, dissolved oxygen sensors, conductivity sensors, and multivariate chemometric models.

Industry 4.0 expands this concept through connected sensors, electronic batch records, automation, data historians, digital twins, artificial intelligence, and predictive maintenance. When implemented effectively, these systems can identify abnormal process trends earlier and support proactive quality decisions.[10]

Table 3: Representative PAT and digital tools used in modern pharmaceutical manufacturing.

PAT tool	What it monitors	Typical application
NIR spectroscopy	Moisture, blend uniformity, API concentration	Blending, drying, coating, tablet testing
Raman spectroscopy	Chemical identity, polymorphs, bioprocess analytes	Reaction monitoring, tablets, bioprocessing
FBRM / particle-size tools	Particle size and chord length distribution	Crystallization and granulation monitoring
Electrochemical sensors	pH, dissolved oxygen, conductivity	Fermentation, cell culture and buffer systems
Digital twins	Virtual process behavior and predictive scenarios	Deviation prediction and process optimization

8. Green Chemistry and Sustainable Bulk Manufacturing

Bulk pharmaceutical processes can generate significant waste, especially due to solvent use, washing, purification, and cleaning operations. Green chemistry aims to reduce environmental impact through safer solvents, solvent recovery, biocatalysis, improved reaction efficiency, continuous processing, and waste minimization.

The environmental factor, or E-factor, expresses the mass of waste generated per kilogram of desired product. Pharmaceutical processes have historically shown high E-factors compared with commodity chemicals, making solvent recycling, water optimization, process intensification, and single-use technologies important sustainability tools.[11]

9. Supply Chain Resilience and Facility Design

Bulk manufacturing facilities are high-investment assets and may become single points of failure if product supply depends on limited geographic locations or specialized equipment. Recent global disruptions have increased attention to regional manufacturing, dual sourcing, modular facilities, inventory strategy, and business-continuity planning.

Facility design must also prevent contamination and cross-contamination. Cleanroom zoning, air handling units, pressure differentials, personnel/material flows, closed systems, isolators, and containment controls are critical, especially for sterile products and highly potent APIs.

Practical resilience strategies include

- Qualified alternate suppliers for critical raw materials
- Validated secondary manufacturing sites or modular production capacity
- Regionalization of key API and drug-product operations
- Robust inventory and demand-forecasting systems
- Digital visibility across procurement, production, quality and logistics.[12]

10. Future Horizons and Emerging Modalities

Future bulk manufacturing is expected to be more modular, automated, data-rich, and adaptable. Factory-in-a-box concepts and modular production units may allow faster response to local demand, shortages, or outbreak situations. Continuous manufacturing may reduce scale-up risk by increasing production duration rather than equipment size.

Nucleic acid therapeutics, including mRNA and oligonucleotides, require different production models from traditional small molecules and biologics. Cell-free enzymatic synthesis, rapid platform changes, and compact production footprints may reshape conventional expectations of manufacturing scale.

11. CONCLUSION

Bulk manufacturing in the pharmaceutical industry is moving from conventional batch-based production toward integrated, science-driven, and digitally controlled manufacturing systems. Small-molecule synthesis, biologics processing, formulation operations, scale-up, validation, QbD, PAT, green chemistry, and supply-chain resilience are all interconnected elements of modern pharmaceutical production.

The future of bulk manufacturing will depend on balancing regulatory compliance, engineering robustness, sustainability, digital innovation, and patient access. Companies that combine strong process understanding with real-time monitoring and lifecycle quality management will be better positioned to deliver reliable, high-quality medicines at commercial scale.[13]

12. Raw Material Management and Supplier Qualification

Raw material management is a critical foundation of bulk pharmaceutical manufacturing because the quality of APIs, excipients, solvents, reagents, filters, culture media, and packaging-contact materials can directly influence process consistency and final product quality. In large-scale operations, even small variations in raw material attributes may be amplified during blending, crystallization, fermentation, filtration, or compression. Therefore, manufacturers establish defined specifications, approved supplier lists, incoming material testing procedures, and risk-based vendor qualification programs.

Supplier qualification generally includes supplier audits, quality agreements, review of certificates of analysis, change-notification expectations, historical performance monitoring, and periodic requalification. For high-risk materials, manufacturers may perform additional identity testing, impurity profiling, microbial testing, endotoxin testing, or functional performance testing. Strong supplier oversight helps reduce variability, prevent contamination events, and support regulatory inspection readiness.[14]

Supplier Qualification Flow
Supplier selection → Quality questionnaire → Supplier audit → Quality agreement → Incoming material testing → Performance monitoring → Periodic requalification

13. Documentation, Data Integrity, and Electronic Batch Records

Documentation is one of the most important control mechanisms in pharmaceutical bulk manufacturing. Manufacturing instructions, batch records, equipment logbooks, cleaning records, deviation reports, environmental monitoring records, analytical data, and change-control documents provide evidence that each operation was performed according to approved procedures. Inadequate or incomplete documentation can create uncertainty regarding batch quality even when the physical product appears acceptable.

Data integrity principles require that records are attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available. Electronic batch records and manufacturing execution systems reduce transcription errors, improve traceability, enable real-time review by exception, and connect production data with quality systems. However, computerized systems must be validated, access must be controlled, audit trails must be reviewed, and data backup procedures must be robust.[15]

ALCOA+ Data Integrity Model
Attributable • Legible • Contemporaneous • Original • Accurate • Complete • Consistent • Enduring • Available
Application in bulk manufacturing: batch records, equipment logs, analytical data, audit trails, electronic signatures, deviation records and change-control documents.

14. Process Validation and Continued Process Verification

Process validation demonstrates, through scientific evidence and documented data, that a manufacturing process can consistently produce material meeting predefined quality requirements. A lifecycle approach is commonly described in three stages: process design, process qualification, and continued process verification. During process design, knowledge from development studies, risk assessments, and scale-up trials is used to define the control strategy. During process qualification, equipment, utilities, facilities, and the process itself are challenged under commercial or representative conditions.[15]

Continued process verification ensures that the validated state is maintained during routine commercial manufacturing. It involves monitoring critical process parameters, critical quality attributes, deviations, trends, yield, cycle time, rejection rates, and customer or complaint data. Statistical process control tools can identify gradual drift before it becomes a quality failure. This approach supports proactive quality management and aligns with modern expectations for ongoing process performance monitoring.

Stage 1 Process Design	→	**Stage 2** Process Qualification	→	**Stage 3** Continued Process Verification
Development knowledge and risk assessment		Commercial-scale qualification and validation batches		Routine monitoring, trending and lifecycle improvement

15. Cleaning Validation and Cross-Contamination Control

Cleaning validation is essential in bulk manufacturing because shared equipment, large product-contact surfaces, complex piping, and hard-to-clean components can create cross-contamination risks. The purpose of cleaning validation is to demonstrate that approved cleaning procedures can consistently remove residues of APIs, excipients, cleaning agents, degradation products, and microbial contamination to acceptable limits.

Modern cleaning programs are risk based and may use health-based exposure limits to define scientifically justified acceptance criteria. Swab sampling, rinse sampling, visual inspection, total organic carbon analysis, and specific analytical methods may be applied depending on the material and equipment design. Cleaning validation is especially important for multi-product facilities, highly potent APIs, hormones, cytotoxic agents, sensitizing compounds, and sterile products.

Cleaning Validation Control Diagram
Product residue → Equipment surface → Cleaning procedure → Sampling method → Analytical testing → Acceptance criteria → Cleaning verification / validation report

16. Sterile Bulk Manufacturing and Aseptic Considerations

Sterile bulk manufacturing introduces additional controls because microbial contamination, endotoxins, particulates, and loss of sterility can directly compromise patient safety. Sterile APIs, biologics, parenteral intermediates, and bulk solutions require controlled environments, validated sterilization or sterile filtration steps, aseptic connections, environmental monitoring, and strict personnel practices.

Aseptic processing relies on cleanroom classification, airflow control, pressure differentials, disinfectant rotation, gowning qualification, sterilization of components, media fills, and routine environmental monitoring. For biologics and large-volume parenterals, bulk holding time, mixing conditions, temperature control, container-closure integrity, and sterile transfer pathways must be validated and monitored throughout the process.[16]

Cleanroom Entry	→	Aseptic Setup	→	Sterile Filtration	→	Bulk Holding	→	Fill-Finish Transfer

17. Highly Potent APIs and Operator Safety

The manufacture of highly potent active pharmaceutical ingredients requires specialized containment strategies to protect operators, the environment, and other products. HPAPIs may include oncology drugs, hormones, immunosuppressants, and compounds with very low occupational exposure limits. In such cases, open handling should be minimized and engineering controls should be prioritized over procedural controls alone.

Containment approaches include isolators, glove boxes, split butterfly valves, contained charging systems, negative-pressure rooms, high-efficiency filtration, closed transfer lines, and validated decontamination procedures. Occupational health assessments, personal protective equipment, exposure monitoring, and waste-handling procedures form part of an integrated containment program. These controls must be built into facility design and process development rather than added after commercial scale-up.

HPAPI Containment Barrier Model
Closed charging → Isolator / glove box → Negative-pressure area → HEPA filtration → Contained waste handling → Operator exposure monitoring

18. Packaging Interface and Bulk Holding Controls

Although bulk manufacturing occurs before final packaging, the interface between bulk production and packaging or filling operations is critical. Bulk tablets, granules, powders, solutions, and biologic drug substances may be stored temporarily before the next process step. During this period, manufacturers must control temperature, humidity, light exposure, container compatibility, microbial risk, segregation risk, and maximum hold time.

Bulk holding studies help establish how long intermediates or drug substances can remain in defined containers under approved conditions without unacceptable changes in assay, impurity profile, dissolution, moisture content, sterility, endotoxin, or physical appearance. Proper labeling, reconciliation, line clearance, and material status control also prevent mix-ups during transfer from manufacturing to packaging or filling areas.[17]

Bulk Holding Control Points
Container compatibility • Temperature control • Humidity control • Light protection • Maximum hold time • Microbial control • Labeling and reconciliation • Transfer documentation

19. Workforce Capability and Training in Bulk Manufacturing

Even highly automated facilities depend on trained personnel who understand GMP, process risks, equipment operation, documentation practices, contamination control, safety requirements, and deviation escalation. Training programs in bulk manufacturing should combine classroom learning, procedure review, hands-on qualification, supervised practice, and periodic effectiveness checks.

Training effectiveness can be strengthened through role-based curricula, visual work instructions, simulation of abnormal situations, refresher programs after deviations, and cross-functional learning between production, quality assurance, quality control, engineering, validation, warehouse, and regulatory teams. A strong quality culture encourages operators to report abnormalities early, follow procedures consistently, and participate in continuous improvement.[18]

Training Lifecycle	→	Procedure Review	→	Practical Qualification	→	Effectiveness Check	→	Refresher / CAPA Training

20. Challenges and Recommendations for Modern Bulk Manufacturing

Despite major technological progress, bulk pharmaceutical manufacturing continues to face challenges related to high capital investment, long validation timelines, regulatory complexity, raw material variability, supply-chain disruption, technology-transfer gaps, skilled workforce shortages, and integration of legacy systems with modern digital tools.

These challenges can delay product launch, increase manufacturing cost, and create quality risks if not proactively managed.

- Build process understanding early through development studies, risk assessments, and design of experiments.
- Use lifecycle validation and continued process verification to maintain control after commercial launch.
- Strengthen supplier qualification and material traceability for critical raw materials.
- Apply PAT and digital tools where they add measurable value to quality decisions.
- Design facilities with contamination control, containment, cleaning, and maintenance in mind.
- Promote a quality culture where documentation accuracy, deviation reporting, and continuous

improvement are treated as shared responsibilities.

Overall, the most successful bulk manufacturing systems are those that connect scientific development, engineering design, quality systems, digital monitoring, sustainability goals, and workforce capability into one integrated lifecycle model. This integrated approach supports reliable production, regulatory confidence, and timely delivery of medicines to patients.[19]

SUMMARY

This review highlights bulk manufacturing as the foundation of the pharmaceutical industry, encompassing the large-scale production of active pharmaceutical ingredients (APIs), biologics, and intermediates before final packaging.

Because small-molecule APIs rely on chemical synthesis while biologics depend on complex living cell cultures, they require vastly different manufacturing strategies. A major industry shift is currently underway from traditional batch manufacturing to continuous manufacturing, which offers smaller equipment footprints, integrated operations, and real-time monitoring to reduce material waste.

Modern pharmaceutical production increasingly relies on digital transformation and a lifecycle approach to quality. By integrating frameworks like Quality by Design (QbD) with advanced technologies like Process Analytical Technology (PAT), digital twins, and automation, manufacturers can achieve deeper process understanding and proactive decision-making. These tools ensure strict data integrity, robust contamination control, and smoother regulatory compliance, which are especially critical for complex biologics and continuous processing.

Ultimately, the future of bulk manufacturing is evolving toward greater sustainability and supply-chain resilience. Incorporating green chemistry, solvent recovery, and modular manufacturing helps reduce environmental impact while mitigating global supply chain disruptions. By combining strong process understanding, digital monitoring, and flexible production platforms, the industry can consistently deliver safe, high-quality medicines to patients efficiently.[19]

CONCLUSION

Bulk manufacturing in the pharmaceutical industry is a vital link between scientific discovery and patient access. It transforms laboratory-developed processes into reliable, large-scale systems capable of producing active pharmaceutical ingredients, biologics, intermediates, and bulk drug products with consistent quality. As industry continues to evolve, bulk manufacturing is no longer limited to conventional production capacity; it now requires strong integration of process science, engineering, automation, quality systems, sustainability, and regulatory compliance.

The review demonstrates that modern pharmaceutical manufacturing depends on a deep understanding of product characteristics and process behavior. Small-molecule APIs require careful control of reaction conditions, impurity formation, crystallization, polymorphism, solvent use, and scale-up challenges. Biologics, on the other hand, require highly controlled biological systems, aseptic handling, purification strategies, and storage conditions to preserve activity, purity, and stability. Both manufacturing pathways demand robust validation, documentation, contamination control, and lifecycle quality management.

A major conclusion from this review is that the future of bulk manufacturing will be driven by the transition from reactive quality control to proactive quality assurance. Quality by Design, Process Analytical Technology, electronic batch records, data integrity practices, continued process verification, and digital twins enable manufacturers to monitor processes in real time and identify risks before they affect product quality. These approaches support better decision-making, reduce batch failures, and improve regulatory confidence.

Sustainability and supply-chain resilience are also becoming essential parts of pharmaceutical manufacturing strategy. Green chemistry, solvent recovery, water and energy optimization, modular facilities, alternate suppliers, regional manufacturing, and digital supply-chain visibility can reduce environmental burden while improving the reliability of medicine supply. These measures are especially important in a global environment where disruptions can directly affect availability of critical therapies.

In conclusion, bulk pharmaceutical manufacturing is progressing toward a more integrated, automated, sustainable, and science-based model. Successful manufacturers will be those that combine strong process understanding, qualified suppliers, trained personnel, validated equipment, digital monitoring, and a culture of continuous improvement. By strengthening these areas, the pharmaceutical industry can enhance product quality, reduce operational risk, meet regulatory expectations, and ensure timely delivery of safe and effective medicines to patients.[20]

REFERENCES

1. Baxendale, I. R., et al. A flow process for the multi-step synthesis of active pharmaceutical ingredients. Journal of Flow Chemistry, 2015; 5(2): 71-75.
2. Byrn, S., et al. (2017). Solid-State Properties of Pharmaceutical Materials. John Wiley & Sons.
3. Gernaey, K. V., et al. Process analytical technology (PAT) in specialty chemical and pharmaceutical industries. Chemical Engineering Science, 2012; 75: 233-245.
4. International Council for Harmonisation (ICH). Guideline Q8(R2): Pharmaceutical Development. Current Step 4 Version.

5. International Council for Harmonisation (ICH). Guideline Q9: Quality Risk Management. Current Step 4 Version.
6. International Council for Harmonisation (ICH). Guideline Q10: Pharmaceutical Quality System. Current Step 4 Version.
7. International Council for Harmonisation (ICH). Guideline Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities).
8. International Council for Harmonisation (ICH). Guideline Q13: Continuous Manufacturing of Drug Substances and Drug Products. Current Step 4 Version.
9. Jameel, F., & Hershenson, S. (Eds.). (2010). Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals. John Wiley & Sons.
10. Lee, S. L., et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. Journal of Pharmaceutical Innovation, 2015; 10(3): 191-199.
11. Plumb, K. Continuous processing in the pharmaceutical industry: Changing the mind set. Chemical Engineering Research and Design, 2005; 83(6): 730-738.
12. Schaber, S. D., et al. Economic analysis of batch versus continuous manufacturing of pharmaceuticals. Industrial & Engineering Chemistry Research, 2011; 50(17): 10083-10092.
13. Sheldon, R. A. The E factor 25 years on: the green metrics of science and technology. Green Chemistry, 2017; 19(1): 18-43.
14. Shukla, A. A., & Thömmes, J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends in Biotechnology, 2010; 28(5): 253-261.
15. Yu, L. X., et al. Understanding quality by design. AAPS Open, 2014; 16(1): 169-183.
16. Dhillon, S. How to write a good scientific review article. The FEBS Journal, 2022; 290(2): 286-291.
17. Ahmad, A., et al. Exploring Principles of Bioreactor Scale-Up: Challenges in Hydrodynamics and Mass Transfer. BioProcess International, 2024; 22(2): 14-22.
18. Kis, Z., et al. Process engineering and scaling up in vitro transcription (IVT) for mass production of mRNA vaccines. Computational and Structural Biotechnology Journal, 2023; 21: 1240-1253.
19. Allmendinger, R., et al. Continuous manufacturing vs traditional batch processing: A multi-attribute decision-making assessment framework for CDMOs. Journal of Pharmaceutical Sciences, 2025; 114(4): 890-905.
20. Vogel, J. H., et al. Single-use vs. stainless steel bulk manufacturing infrastructure: A holistic life cycle assessment and carbon footprint evaluation. Biotechnology Progress, 2022; 38(3): e3245. Current Step 4 Version.